` OPK (OPKO Health Inc) vs S&P 500 Comparison - Alpha Spread

OPK
vs
S&P 500

Over the past 12 months, OPK has underperformed S&P 500, delivering a return of -14% compared to the S&P 500's +12% growth.

Stocks Performance
OPK vs S&P 500

Loading
OPK
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OPK vs S&P 500

Loading
OPK
S&P 500
Difference
www.alphaspread.com

Performance By Year
OPK vs S&P 500

Loading
OPK
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
OPKO Health Inc vs Peers

S&P 500
OPK
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

OPKO Health Inc
Glance View

In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.

OPK Intrinsic Value
1.9 USD
Undervaluation 27%
Intrinsic Value
Price
Back to Top